Abstract: Disclosed herein are ruthenium arene Schiff-base complex and uses thereof. The ruthenium arene Schiff-base complex disclosed herein has the structure of formula (I), wherein, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12 are independently H, alkyl, alkoxyl, or halo; R13, R14, R15, R16, and R17 are independently H, alkyl, alkoxyl, hydroxy, halo, —C(?NH)NH2, —SO3H, —SO2NH2, —NR?R?, or —CONH2; or R13 and R14 are taken together to form a benzene ring, while R15, R16, and R17 are independently H, alkyl, alkoxyl, hydroxy, halo, —C(?NH)NH2, —SO3H, —SO2NH2, —NR?R?, or —CONH2; or R14 and R15 are taken together to form a benzene ring, while R13, R16, and R17 are independently H, alkyl, alkoxyl, hydroxy, halo, —C(?NH)NH2, —SO3H, —SO2NH2, —NR?R?, or —CONH2; R? and R? are independently H or alkyl; the alkyl is optionally substituted with one or more halo or hydroxy, or hydroxy; and Y is a counter anion. Also disclosed herein are methods of treating malignant neoplasm in a subject.

Abstract: The present invention relates to a compound of following formula (I), which is a novel prodrug of biguanide derivatives: (I). The present invention also relates to the preparation and methods of using the compound. In particular, the invention relates to prodrugs wherein metformin and phenformin are attached to AuIII cyclometalated backbone to form novel AuIII prodrugs of metformin or phenformin with improved anticancer effects.

Abstract: Disclosed herein are ruthenium arene Schiff-base complex and uses thereof. The ruthenium arene Schiff-base complex disclosed herein has the structure of formula (I), wherein, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12 are independently H, alkyl, alkoxyl, or halo; R13, R14, R15, R16, and R17 are independently H, alkyl, alkoxyl, hydroxy, halo, —C(?NH)NH2, —SO3H, —SO2NH2, —NR?R?, or —CONH2; or R13 and R14 are taken together to form a benzene ring, while R15, R16, and R17 are independently H, alkyl, alkoxyl, hydroxy, halo, —C(?NH)NH2, —SO3H, —SO2NH2, —NR?R?, or —CONH2; or R14 and R15 are taken together to form a benzene ring, while R13, R16, and R17 are independently H, alkyl, alkoxyl, hydroxy, halo, —C(?NH)NH2, —SO3H, —SO2NH2, —NR?R?, or —CONH2; R? and R? are independently H or alkyl; the alkyl is optionally substituted with one or more halo or hydroxy, or hydroxy; and Y is a counter anion. Also disclosed herein are methods of treating malignant neoplasm in a subject.

Abstract: The present invention relates to organometallic compounds useful in the treatment of metastasis. The organometallic compounds comprise a ligand that is convalently bound to a bioactive compound, which is an inhibitor of a resistance pathway or a derivative thereof. Preferably, the organometallic compounds are half-sandwich (“piano-stool”) compounds. The compounds of the present invention offer a high variability with respect to the bioactive compound and to the nature of the ligand bound to a central transition metal.

Abstract: The present invention relates to organometallic compounds useful in the treatment of metastasis. The organometallic compounds comprise a ligand that is covalently bound to a bioactive compound, which is an inhibitor of a resistance pathway or a derivative thereof. Preferably, the organometallic compounds are half-sandwich (“piano-stool”) compounds. The compounds of the present invention offer a high variability with respect to the bioactive compound and to the nature of the ligand bound to a central transition metal.

Abstract: The present invention relates to novel organometallic compounds for use as a medicine, in particular in photodynamic therapy against various diseases, such as cancer or inflammatory and/or immune disorders. The compounds comprise a central porphyrin or phtalocyanine backbone to which ligand linkers coordinated to at least one transition metal are attached. Eta-5 or eta-6 arenes further bind to the transition metal. According to a preferred embodiment, the compound is a tetranuclear Ruthenium (+II) complex.

Abstract: The present invention relates to organometallic compounds useful in the treatment of metastasis. The organometallic compounds comprise a ligand that is covalently bound to a bioactive compound, which is an inhibitor of a resistance pathway or a derivative thereof. Preferably, the organometallic compounds are half-sandwich (“piano-stool”) compounds. The compounds of the present invention offer a high variability with respect to the bioactive compound and to the nature of the ligand bound to a central transition metal.